Personally, I try to pay as little attention as possible to the administration’s current, contradictory federal pronouncements on tariffs. But in terms of biosimilars (and generics), that is not truly possible. If high tariffs on certain countries are implemented, the damage to a biosimilar industry facing several existential challenges today can be easy to grasp … Continue reading Tariff Policy and Biosimilars: Dancing Around Another Threat to the Industry